Filter by: patients
Home > Community Treatment Reports and Side Effects > MS Phase 3 Study CombiRx Treatment Report
What is MS Phase 3 Study CombiRx?

NCT00211887 is a multi-center, double-blind, randomized study comparing the combined use of interferon beta-1a and glatiramer acetate to either agent alone in patients with relapsing-remitting multiple sclerosis. Other study IDs include: NS045719, 02-0526, CRC, U01 NS45719 and CombiRx.

Reported Schedules

  1 other daily
  1 Number of Patients: 1  

Reported Duration See details about how long patients take this treatment ▼

Currently Using MS Phase 3 Study CombiRx

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Report created on May 28, 2012.